TheRas, Inc. (d/b/a BridgeBio Oncology Therapeutics) (“BBOT”)

TheRas, Inc. (d/b/a BridgeBio Oncology Therapeutics) (“BBOT”) is passionate about developing advanced therapies and delivering transformative medicines to treat patients who suffer from advanced cancers. BBOT provides access to our investigational therapies through enrollment in our ongoing clinical trials. For ongoing clinical trials on BBOT’s investigational therapies currently in development, please visit https://clinicaltrials.gov.
BBOT also recognizes the importance of utilizing the applicable regulatory and legal pathways for providing access to our investigational therapies when patients with life-threatening diseases have exhausted all available treatment options and are not eligible for clinical trials. At certain point when efficacy and safety profile of specific molecule is reasonably established to allow BBOT for risk/benefit assessment, BBOT may be able to provide patients access to its investigational medicines outside of a clinical trial if certain conditions are met.
The use of investigational medicines outside of a clinical trial is known under various terms such as Pre-approval Access, Expanded Access, or Named Patient Programs (also widely referred to as compassionate use). Requests for access to investigational products under these circumstances must be made by treating physicians directly to BBOT. Upon receipt of an unsolicited request by a prescribing healthcare professional, when permitted by local regulations, BBOT may consider access requests from treating physicians for patients with no viable therapeutic alternatives.